- Home
- / Lucid Diagnostics
Lucid Diagnostics
Stock Price
$1
2024-10-29
Market Capitalization
$48.6 M
2024-10-29
Revenue
$4.7 M
FY, 2025
Lucid Diagnostics Summary
Company Summary
- Overview
- Lucid Diagnostics is a commercial-stage medical diagnostics technology company developing tests for patients with gastroesophageal reflux disease (GERD). It offers the EsoCheck cell collection device and the EsoGuard esophageal DNA test.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- New York, NY, US | view all locations
- Website
- https://www.luciddx.com/
- Cybersecurity rating
Table of Contents
Key People
Dennis Mcgrath, Chief Financial Officer
David Wurtman, Chief Medical Officer
Shaun O'Neil, Chief Commercial Officer
LocationsView all
1 location detected
New York, NY HQ
United States
One Grand Central Place, Suite 4600
Lucid Diagnostics Financials
Summary Financials
- Revenue (Q1, 2026)
- $1.3M
- Gross profit (Q1, 2026)
- ($369.0K)
- Net income (Q1, 2026)
- ($13.9M)
- Cash (Q1, 2026)
- $27.9M
- EBIT (Q1, 2026)
- ($12.1M)
- Enterprise value
- $72.7M